Table 3.
Pharmacologic modulators of the Hippo pathway.
| Key | Compound | Mechanism | References |
|---|---|---|---|
| A | Fostriecin derivative | Inhibits PP2A | (210) |
| B | FTY720 | Activates PP2A | (211) |
| C | 9E1 | Inhibits MST1 activity | (212) |
| D | C19 | Activates MST/LATS | (213) |
| E | TM-25659 | Modulates TAZ localization | (214) |
| F | Pyrrolidone 1 | 14-3-3 protein stabilizer | (215) |
| G | Verteporfin | Inhibits YAP-TEAD interaction | (49) |
| Cyclic YAP-like peptide | Inhibits YAP-TEAD interaction | (205) | |
| VGLL4-like peptide | Inhibits YAP-TEAD interaction | (216) | |
| ABT-263, TW37 | Inhibit BCL-xL (a YAP target) | (208, 217) | |
| H | Dasatinib | Inhibits β-catenin-YAP-TBX5 complex | (58) |
| I | Epinephrine | Activates LATS through GPCRs | (29, 218) |
| Dobutamine | Causes YAP phosphorylation | (219) | |
| J | Phenoxodiol | SPHK1 inhibitor | (220, 221) |
| BrP-LPA | LPA analog that blocks LPA receptors | (222) | |
| Thrombin | Acts on PARS to activate YAP | (223) | |
| K | LT3015 Sphingomab | Monoclonal antibodies to LPA, S1P | (224–226) |
| L | Ibudilast | Inhibits PDE | (218, 227, 228) |
| M | Statins | HMG-CoA reductase inhibitors | (100, 101) |
| N | Y27632 | RHO/ROCK inhibitors | (113, 116, 229) |
| HA1077 | |||
| Botulinum toxin C3 | |||
| O | Blebbistatin | F-actin destabilizers | (113, 115, 116) |
| Cytochalasin D | (114–116) | ||
| Latrunculin A/B | (113, 115, 116) | ||
| ML7 | (115) | ||
| P | WNT (or other pathway) modulators | (see Regulation Through Cross-Talk with Other Pathways and Hippo Modulation to Augment Other Pathway-Directed Therapies) |